Search Results - coronavirus

7 Results

Sort By:

Human Antibodies Against Middle East Respiratory Syndrome Coronavirus

Abstract: No effective therapeutics or vaccines against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) are available. The human-to-human aspect of transmission and the high mortality rate associated with MERS-CoV infection have raised concerns over the potential for a future MERS-CoV pandemic and emphasized the need for development of effective...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Tianlei Ying, Tina Ju, Kwok Yuen

Keywords(s): ANTIBODY, CORONAVIRUS, MERs, middle east respiratory syndrome

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease

Single Domain Antibodies Targeting the S2 Subunit of SARS-CoV-2 Spike Protein

Abstract: The COVID-19 pandemic is a worldwide public health crisis with over 100 million confirmed cases and 2.4 million deaths as of February 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. Almost all the neutralizing antibodies targeting SARS-CoV-2 that are in development recognize the receptor binding domain (RBD) on the spike...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Zhijian Duan, Jesse Buffington

Keywords(s): : COVID-19, ANTIBODY, Camel Nanobody, CORONAVIRUS, HO, Infectious Diseases, Nanobodies, Pandemic, SARS-CoV-2, Shark Nanobody, therapeutic, Vaccine

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease

Therapeutics Against Pathogenic Coronaviruses

Abstract: The COVID-19 pandemic is a worldwide public health crisis with over 440 million confirmed cases and 6.0 million deaths as of March 2022. COVID-19 is caused by a novel coronavirus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). While there are several vaccines available for COVID-19, there are few therapeutics available...

Published: 4/8/2024 | Inventor(s): Melvin DePamphilis, Matthew Frieman, Arup Chakraborty

Keywords(s): CORONAVIRUS, COVID-19, Depamphilis, Eunice Kennedy Shriver National Institute of Child Health an, Infectious Diseases, MER-CoV, NICHD, PIKfyve Phosphatidyl Linositol Kinase Inhibitors, SARS-CoV, SARS-CoV-2, virus

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease

Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron

Abstract: Since its emergence in 2019, COVID-19 infected over 600 million people and over 6 million people have died from the disease. COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Neutralizing antibodies have been developed to bind to the receptor binding domain (RBD) on the spike (S) protein. Blocking the interaction of the RBD...

Published: 7/29/2024 | Inventor(s): Mitchell Ho, Jessica Hong, Jesse Buffington, Zhijian Duan

Keywords(s): ANTIBODY, Camel Nanobody, CORONAVIRUS, COVID-19, HO, Infectious Diseases, Nanobodies, Pandemic, SARS-CoV-2, therapeutic, Vaccine

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, Application > Therapeutics, Collaboration Sought > Licensing

Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19

Abstract: The COVID-19 pandemic is a worldwide public health crisis with over 100 million confirmed cases and 2.4 million deaths as of February 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. SARS-COV-2 infects hosts via its spike (S) protein. The S protein contains the receptor binding domain (RBD) that binds to the angiotensin converting...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Jessica Hong

Keywords(s): ANTIBODY, antigen-binding fragment, CORONAVIRUS, COVID-19, HO, NANOBODY, respiratory INFECTION, S Protein, SARS-CoV-2, spike protein

Category(s): TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics

Recombinant Chimeric Bovine/Human Parainfluenza Virus 3 Expressing SARS-CoV-2 Spike Protein and Its Use

Vaccines for SARS-CoV-2 are increasingly available under emergency use authorizations; however, indications are currently limited to individuals twelve (12) years or older. They also involve intramuscular immunization, which does not directly stimulate local immunity in the respiratory tract, the primary site of SARS-CoV-2 infection, shedding and spread....

Published: 7/25/2024 | Inventor(s): Shirin Munir, Cindy Luongo, Peter Collins, Cyril Le Nouen, Xueqiao Liu, Ursula Buchholz

Keywords(s): 2, ACUTE, Attenuated, B/HPIV3, BOVINE/HUMAN, chimeric, CORONAVIRUS, DC5BXX, DC5XXX, DCXXXX, DDXXXX, DEXXXX, DXXXXX, Expression, GLYCOPROTEIN, PIV3, respiratory, S, SARS-CoV-2, SEVERE, spike, Syndrome

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Vaccines, Application > Research Materials

Prefusion Coronavirus Spike Proteins and Their Use

Coronaviruses (CoVs) can cause severe respiratory disease with high fatality rates in humans. The 2002-2003 SARS-CoV epidemic resulted in 8098 cases and 744 deaths, and MERS-CoV, which emerged in 2012, has resulted in 2144 cases and over 750 deaths as of March 2018. Currently, there are no effective prophylactic or therapeutic measures, and because...

Published: 7/25/2024 | Inventor(s): Masaru Kanekiyo, Michael Joyce, Kizzmekia Corbett, Hadi Yassine, Jason McLellan, Christopher Cottrell, Nianshuang Wang, Jesper Pallesen, Hannah Turner, Robert Kirchdoerfer, Andrew Ward, Barney Graham

Keywords(s): CORONAVIRUS, DC5BXX, proteins, Stabilized, VACCINATION

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Vaccines